Although an investigation showed no significant correlation between the CD8/Foxp3 ratio and survival in ovarian cancer [41], the CD8/Foxp3 ratio was found to be a promising prognostic marker in advanced HPSCC. This evidence concerns the gene FOXP3 and ovarian cancer.